###### Summary box

-   Health economic evaluations and contextualised cost-effectiveness analyses (CEAs) are valuable tools for priority setting in emerging demographic, epidemiological and health system changes in low-income countries.
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-   This is the first published comprehensive comparison of contextualised CEAs for multiple health interventions targeting both non-communicable diseases (NCDs) and maternal, neonatal and child health.

-   Scaling up maternal, neonatal and child health interventions, together with primary preventions of cardiovascular diseases, gives higher expected health benefits and lower budget impacts than investments in other NCD interventions.

-   The contextualised CEA method here is user-friendly and gives a clear visualisation of the opportunity cost when deciding on national healthcare investments.

Introduction {#s1}
============

Globally, most countries have committed themselves to move towards universal health coverage (UHC) which is a key subtarget of the Sustainable Development Goals for health.[@R1] UHC has been defined as all people receiving quality health services that meet their needs without being exposed to financial hardship in paying for the services.[@R4] Given resource constraints, this does not entail all possible services, but a comprehensive range of essential services that is well aligned with other social goals.[@R5] Competing priorities within the health sector and across other sectors necessitates careful work in defining an optimal and feasible path to UHC.

Cost-effectiveness analysis (CEA) identifies interventions that maximise population health, an important objective in resource constrained health systems.[@R4] Health economic evaluations are now being used in several ongoing national benefit package revisions in low-income countries.[@R7] Ranking interventions by cost-effectiveness can be used to explicitly identify the health services that deliver the highest health impact for the lowest cost. While recent academic debates highlight the need to include concerns for fairness issues like financial risk protection[@R8] and priority to worse off,[@R5] close attention to evidence about health maximisation and distribution is important in policy decisions.[@R5]

More health economists are needed in low-income countries. The majority of health economic evaluations are conducted in high-income countries. Regional CEAs may be the only available evidence in a low-income country. Often, important interventions lack evidence from health economic evaluations and fiscal analyses. Regional CEAs should be translated with caution to country levels, and preferably contextualised and parametrised to the respective country.[@R10] Local demography, epidemiology and health system may have large impact on expected costs and health effects. CEAs and results from one setting cannot easily be transferred to another.[@R11] One way of overcoming this is to contextualise methods, data and analyses to ensure that models fit and reflect national health system objectives and constraints. Involvement of local health economists or other with similar skills is important in this work.

This paper presents a summary of results from three separate contextualised CEAs targeting maternal, newborn and child health (MNCH), mental and neurological conditions and cardiovascular diseases (CVD) from Ethiopia.[@R12] In doing this, a total of 61 interventions are rank ordered based on the incremental cost-effectiveness rates (ICERs). We discuss lessons learnt from the initial analytical processes and how this evidence can inform priority setting in Ethiopia.

Ethiopian context {#s2}
=================

Ethiopia is among the countries that shows a strong commitment to implement the UHC as part of aiming for the Sustainable Development Goals (SDG) for health.[@R15] With a GDP of US\$ 772 per capita (2018),[@R16] Ethiopia aspires to *'* *...transition into a lower-middle income country by 2025 and a middle-middle income country by 2035.*'[@R17] Aligned with that, the Ministry has conducted an 'envisioning of the health sector' towards UHC, where they identified good-performing and poor-performing lower middle-income countries in order to identify possible policy options that Ethiopia can learn from.[@R17] Ethiopia developed an Essential Package of Health Services in 2005 that is currently under substantial revision.[@R20] While Ethiopia has made significant progress in improving access to primary care over the past decades, the coverage remains low for most essential health services at a primary and specialised level (see [table 1](#T1){ref-type="table"}).[@R21] Health economic evaluations and fiscal space analyses of multiple interventions are needed with emerging non-communicable diseases and injuries (NCDI) and a still unfinished agenda for many of the paediatric, obstetric and infectious disease interventions.

###### 

Current coverage of 13 key maternal, child and neonatal health services in Ethiopia[@R12]

  Maternal and neonatal interventions                 Baseline coverage (%)
  --------------------------------------------------- -----------------------
  Neonatal resuscitation (institutional)              26
  Kangaroo mother care                                22
  Newborn sepsis---Injectable antibiotics             26
  Antibiotics for pPRoM                               3
  Management of pre-eclampsia and eclampsia           3
  Antenatal corticosteroids for preterm labour        0
  Induction of labour (beyond 41 weeks)               3
  Safe abortion                                       37
  Maternal sepsis case management                     22
  Active management of the 3rd stage of labour        23
  Tetanus toxoid (pregnant women)                     49
  Syphilis detection and treatment (pregnant women)   31
  Calcium supplementation                             0

pPRoM, preterm premature rupture of membrane.

Maternal, reproductive, neonatal, child and adolescent health is a cornerstone in the Health Sector Transformation Plan (2015--2020) in Ethiopia.[@R17] However, such services are far from universally available, and further scale-up are likely to compete with a range of services for NCDI. Only 28% of all deliveries were conducted by a skilled person according to Ethiopia Demographic and Health Survey (2016).[@R21] The launch of the National Mental Health Strategy in 2012 and the National Strategic Action Plan for Prevention and Control of NCDIs in 2014 indicates a higher priority to mental and substance use disorders.[@R22] A national commission on NCDI in Ethiopia recently launched an essential healthcare package for prioritised NCDI interventions.[@R24] A majority of the mental health and neurological and CVD interventions are currently not publicly available, and the costs are therefore covered by the patients and their households in Ethiopia.[@R25] Taking UHC as an overarching goal, Ethiopia envisages ambitious and progressive scale-up of a comprehensive range of services mainly through primary healthcare and the Health Extension Program.[@R18] So far, only a few CEAs are made based on contextualised data from Ethiopia.

Selecting policy relevant interventions {#s3}
=======================================

After consulting with the Ministry of Health officials in Ethiopia on what they found as the collection of the most policy relevant interventions, we assessed cost-effectiveness, targeting three broad disease categories separately: (1) treatment of newborn disorders (sepsis and other infections, respiratory distress, premature births, tetanus, still-births, birth asphyxia and complications during labour) and maternal disorders (sepsis, hypertensive disorders of pregnancy, intrapartum events, and unsafe abortion); (2) treatment of depression, schizophrenia, bipolar disorder and epilepsy and (3) prevention and treatment of myocardial infarction and stroke. The range of interventions assessed was selected through an active participation of key policy makers in the Federal Ministry of Health (FMOH) in view of the envisaged policy direction: (i) relevance to the scale-up of primary healthcare and (b) emerging challenges from NCDIs such as CVD and mental health.

Calculating best buys {#s4}
=====================

Population based models were used to estimate costs and effectiveness of the selected interventions. WHO-CHOICE regional CEA models were substantially revised with Ethiopian epidemiological, demographic, efficacy and cost data whenever possible. Details of the methods have been reported separately in the respective CEA papers.[@R12] The currency year in each of the contextualised CEAs are here inflation-adjusted to 2017 values to facilitate comparisons across all interventions. A null scenario with no coverage of services was used as baseline for each cardiovascular, mental and neurological intervention to estimate ICERs. Therefore, the cheapest interventions presented here can actually be dominated since the null scenario of the mutually exclusive interventions are not presented in the tables. Current coverage was used to calculate ICERs of maternal, child and neonatal health services.[@R12] Target coverages for all cardiovascular and maternal, child and neonatal health interventions were set to 20%, which was considered a realistic and not too ambitious coverage increase of these interventions in an Ethiopia setting. The existing National Mental Health Strategy in Ethiopia was used as a reference to set target coverage for treatment of depression (30%), bipolar disorder (50%), schizophrenia (75%) and epilepsy (75%).[@R22]

[Figure 1](#F1){ref-type="fig"} and [table 2](#T2){ref-type="table"} show the results from the three contextualised CEAs. The ICERs for the interventions vary widely with an order of magnitude ranging by up to several hundred folds.

![Contextualised cost-effectiveness of a complete set of interventions---ranking of 13 maternal and child health, 19 mental and neurological and 29 cardiovascular interventions by cost-effectiveness.](bmjgh-2018-001320f01){#F1}

###### 

Contextualised cost-effectiveness of a complete set of interventions---ranking of 13 maternal and child health, 19 mental and neurological and 29 cardiovascular interventions by their respective ICER

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Condition                                                                Interventions                                                Annual cost (US\$)\*   DALYs averted   ICER\         Rank
                                                                                                                                                                               (US\$/DALY)   
  ------------------------------------------------------------------------ ------------------------------------------------------------ ---------------------- --------------- ------------- ------
  Major depressive disorder                                                Older antidepressants (TCA)                                  15 935 000             24 300          D             --

  Newer antidepressants (SSRI)                                             18 542 000                                                   29 100                 636             17            

  Psychotherapy                                                            68 138 000                                                   29 100                 D               --            

  Older antidepressants (TCA) and psychotherapy                            69 632 000                                                   34 100                 D               --            

  Newer antidepressants (SSRI) and psychotherapy                           71 402 000                                                   40 600                 4621                          

  Major depressive disorder                                                Maintenance: Older antidepressants (TCA) and psychotherapy   62 081 000             58 900          1054          18

  Maintenance: Newer antidepressants (SSRI) and psychotherapy              65 789 000                                                   62 200                 1135            19            

  Schizophrenia                                                            Typical antipsychotics                                       23 639 000             4900            D             --

  Atypical antipsychotics                                                  23 635 000                                                   6000                   D               --            

  Typical antipsychotics+psychosocial treatment                            25 058 000                                                   9000                   D               --            

  Atypical antipsychotics+psychosocial treatment                           26 252 000                                                   10 600                 2465            24            

  Case id+management: Typical antipsychotics and psychosocial treatment    30 097 000                                                   11 100                 D               --            

  Case id+management: Atypical antipsychotics and psychosocial treatment   31 290 000                                                   11 600                 5211            28            

  Bipolar affective disorder                                               Older mood stabiliser (Lithium)                              28 560 000             17 600          1627          22

  Older mood stabiliser (Lithium) and psychosocial treatment               33 045 000                                                   19 300                 2518            25            

  Newer mood stabiliser (Valproate)                                        31 913 000                                                   18 600                 D               --            

  Newer mood stabiliser (Valproate) and psychosocial treatment             36 418 000                                                   20 500                 2819            26            

  Epilepsy                                                                 Older antiepileptic treatment (Phenobarbital)                30 874 000             68 900          448           16

  Newer antiepileptic treatment (Carbamazepine)                            67 170 000                                                   68 900                 HIGH            31            

  Acute ischaemic heart disease                                            ACE inhibitor                                                3 082 000              300             D             --

  Beta-blocker                                                             3 084 000                                                    600                    D               --            

  ASA                                                                      3 087 000                                                    1000                   D               --            

  Streptokinase                                                            3 662 000                                                    1200                   D               --            

  ASA+clopidogrel                                                          3 094 000                                                    1400                   D               --            

  ASA+streptokinase                                                        3 692 000                                                    2100                   D               --            

  ASA+streptokinase+ACE inhibitor+beta-blocker                             3 790 000                                                    2100                   D               --            

  ASA+streptokinase+ACE inhibitor                                          3 700 000                                                    2400                   1544            21            

  Primary PCI                                                              10 755 000                                                   2700                   D               --            

  ASA+clopidogrel+PCI                                                      11 032 000                                                   4000                   4529            29            

  Post-acute IHD                                                           Statin                                                       3 552 000              300             D             --

  Beta-blocker                                                             3 281 000                                                    500                    D               --            

  ACE inhibitor                                                            3 306 000                                                    500                    D               --            

  ASA+beta-blocker                                                         3 337 000                                                    700                    D               --            

  ASA+beta-blocker+statin                                                  3 659 000                                                    1000                   D               --            

  ASA+beta-blocker+statin+ACE inhibitor                                    3 736 000                                                    1600                   2400            23            

  Acute ischaemic stroke                                                   ASA                                                          3 282 000              100             52 102        30

  Post-acute stroke                                                        ACE inhibitor                                                3 730 000              900             D             --

  ASA                                                                      3 707 000                                                    1000                   D               --            

  ASA+statin                                                               4 414 000                                                    2400                   D               --            

  ASA+statin+ACE inhibitor                                                 4 518 000                                                    3300                   1376            20            

  Primary prevention of CVD                                                Individual cholesterol treatment((tot. chol.\>6.2 mmol/L)    6 059 000              8800            D             --

  Individual cholesterol treatment (tot. chol. \>5.7 mmol/L)               13 778 000                                                   19 100                 D               --            

  Individual hypertension treatment (SBP\>160 mm Hg)                       9 510 000                                                    98 900                 D               --            

  Combination drug treatment for absolute risk of CVD\>35%                 9 315 000                                                    125 700                74              5             

  Individual hypertension treatment (SBP \>140 mm Hg)                      25 196 000                                                   125 700                D               --            

  Combination drug treatment for absolute risk of CVD\>25%                 12 753 000                                                   128 000                D               --            

  Combination drug treatment for absolute risk of CVD\>15%                 18 696 000                                                   153 900                333             14            

  Combination drug treatment for absolute risk of CVD\>5%                  34 835 000                                                   190 400                442             15            

  Neonatal disorders                                                       Neonatal resuscitation (institutional)                       353 000                54 700          6             1

  Neonatal disorders                                                       Kangaroo mother care                                         287 000                36 700          8             2

  Neonatal disorders                                                       Newborn sepsis---Injectable antibiotics                      906 000                52 100          17            3

  Maternal/neonatal disorders                                              Antibiotics for pPRoM                                        591 000                8500            69            4

  Neonatal disorders                                                       Antenatal corticosteroids for preterm labour                 837 000                8600            98            6

  Maternal disorders                                                       Safe abortion                                                737 000                6800            108           7

  Maternal/neonatal disorders                                              Management of pre-eclampsia and eclampsia                    519 000                4800            108           7

  Neonatal disorders                                                       Induction of labour (beyond 41 weeks)                        393 000                2600            152           9

  Maternal/neonatal disorders                                              Tetanus toxoid (pregnant women)                              2 688 000              16 000          168           10

  Maternal disorders                                                       Maternal sepsis case management                              1 151 000              5200            220           11

  Maternal/neonatal disorders                                              Syphilis detection and treatment (pregnant women)            1 522 000              6800            224           12

  Maternal/neonatal disorders                                              Active management of the third stage of labour               1 617 000              6600            244           13

  Maternal/neonatal disorders                                              Calcium supplementation                                      4 949 000              1600            3081          27
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*2018 US\$.

ACE, angiotensin-converting enzyme; ASA, acetylsalisylic acid; CVD, cardiovascular disease; ICER, incremental cost-effectiveness rate; IHD, ischemic heart disease; PCI, percutaneous coronary intervention; pPRoM, preterm premature rupture of membrane; SBP, systolic blood pressure; SSRI, selective serotonin reuptake inhibitors; TCA, tricyclic antidepressants.

[Figure 2](#F2){ref-type="fig"} visualises the budget impact of investing in the 31 non-dominated interventions from [table 1](#T1){ref-type="table"}. A US\$1 increase per capita in the annual Ethiopian health budget, currently at US\$28,[@R16] could allow inclusion of around half of these interventions into the health system.

![Cost-effectiveness (DALYs averted per \$1000), bar heights and cumulative budget impact, bar width, of all 31 interventions that are not dominated, ordered from the lowest (left) to highest (right) cost-effectiveness (numerical values, including net health benefits (with WTP threshold \$2000/DALY averted), are shown at bottom).](bmjgh-2018-001320f02){#F2}

Ochalek *et al* argue that information of ICERs are not sufficient for setting priorities between interventions since the size of potential health impacts are not specified with such rates.[@R7] They argue that estimates of net DALYs averted best captures potential health impacts, and net health benefit of each intervention is presented at the bottom of [figure 2](#F2){ref-type="fig"}. In our calculations of net health benefits, we set the Ethiopian willingness to pay threshold at US\$2000 per DALY averted, acknowledging that this a rough and arbitrary threshold. More in-depth financial costing analysis is needed for better precision. Nine of the interventions ([table 2](#T2){ref-type="table"}) are expected to give negative or zero net health benefits in return with a US\$2000 budget threshold. Priority to interventions with expected negative net health benefits, for example, primary percutaneous coronary intervention (PCI) for myocardial infarction, calcium supplementation during pregnancy and some of the mental health interventions, would thus cause more harm than good for population health in Ethiopia---if the willingness to pay threshold is less than US\$2000 per DALY averted.

Lessons learnt {#s5}
==============

To the best of our knowledge, this is the first comparison of comprehensive contextualised CEAs for health interventions in an Ethiopia setting. By using standardised and comparable methods and data inputs, we are able to produce a league table allowing reasonable comparability across intervention categories. We describe CEAs as contextualised if they include national analysts and use country-specific input for either costs, epidemiology, demography, baseline coverage or effects. Several of the coauthors are Ethiopians and have experience with policy and planning, and they contributed substantially to the data collection and analysis. This was important for making the analyses policy relevant and locally relevant. In addition, this is important capacity building and a way to train people in Ethiopia in health economic methods. Defining, expanding and financing key services are arguably the most important first steps in the process of translating results from CEAs to actual health policy. Below, we discuss our lessons learnt for each category of interventions in detail and point at the contribution these contextualised CEAs may provide to policy makers as well as its challenges and limitations.

Lessons: maternal and child health {#s5-1}
----------------------------------

Almost all of the maternal and neonatal health interventions have low ICERs. The total annual cost of increasing coverage of all maternal and neonatal interventions by 20% is estimated to be around US\$21 million (US\$0.2 per capita), with an aggregated expected net health benefit of around 204 000 DALYs averted. These services are also stated as high priority services in Ethiopian policy documents. Yet, they have a low effective coverage levels in Ethiopia. In a recent Lancet publication, Ruducha *et al* show how child mortality has decreased substantially in Ethiopia, and now neonatal morality makes up 46% of the under-5-mortality.[@R28] For most policy makers, it is well known that maternal and child care services are effective and efficient interventions, while neonatal interventions have received less attention. In Memirie *et al*'s study, we found that introducing neonatal resuscitation, kangaroo mother care and treatment of newborn sepsis with injectable antibiotics in neonatal intensive care units have the lowest ICERs. The ICERs for these interventions are between US\$6 and US\$17/DALY averted and the expected net health benefits are expected to be 143 700 DALYs averted in total, at a 20% incremental overage level.[@R12] In the latest demographic health survey from Ethiopia (2016), the neonatal mortality rate is 29 deaths per 1000 deliveries. However, only 30% of children\<6 months with fever seek care at a health facility and 28% of all births are delivered by a skilled obstetrician or midwife or other trained skilled health personnel. While maternal and child health interventions have been, and still are high priority in Ethiopia, most of the NCD interventions analysed here have higher ICERs. There is a risk that a priority to NCDI interventions can diminish the priority to maternal and neonatal interventions and reduce population health levels. Solberg *et al* are some of the many arguing that saving a newborn life has relatively less value than saving older children or adult lives.[@R29] If less value is given to save newborn lives, it may be justifiable to diverge from obstetric and neonatal interventions. Contextualised CEAs provide evidence and can visualise such trade-offs explicitly in fair and deliberative decision-making processes.

Lessons: cardiovascular diseases {#s5-2}
--------------------------------

Of note is that most of the CVD interventions in [figure 1](#F1){ref-type="fig"} and [table 2](#T2){ref-type="table"} were not included in the 2005 essential health services package.[@R30] Many of these are now considered for being included in the package as part of the current revision. Primary prevention of CVD has one of the lowest ICERs of all 61 interventions. In the contextualised CEA by Tadesse *et al*, we found that primary prevention of CVD in primary healthcare, at a health centre and primary hospital level, with an absolute risk-based approach cost between US\$74 and US\$442 /DALY averted (or between 2.3 and 13.5 DALYs averted per US\$1000 invested). ICERs, health benefits and budget impact vary by risk eligibility threshold. A high threshold policy, \>35% 10-year risk of CVD, is estimated to give 13.5 DALYs in return per US\$1000 invested (US\$74/DALY averted), avert 121 000 DALYs and cost US\$9.3 million in total. A low risk policy, 5% 10-year risk of CVD, is estimated to give 2.3 DALYs in return per US\$1000 invested (US\$442/DALY averted), avert 28 000 DALYs and cost US\$34.8 million in total. The reason why ICERs increase with lower risk thresholds is that the number of CVD events prevented per person taking antihypertensives and statins diminishes with lower eligibility risk thresholds. Even if primary prevention has low ICERs, it is important to think carefully how this service is best integrated into the health system during a scale-up. The most advanced treatment of myocardial infarction (PCI and clopidogrel) has an ICER at US\$4529 per DALY averted (0.2 DALYs averted per US\$1000 invested) and negative net health benefits (−2000 DALYs averted), at a 20% incremental coverage level and a budget threshold of US\$2000/DALYs. Streptokinase is slightly less efficacious than PCI, but has a much lower ICER (US\$1544/DALY averted or 0.6 DALYs averted per US\$1000 invested) and a net benefit at around 500 DALYs averted in an Ethiopian setting.

The health system in Ethiopia has up to now given high priority to interventions targeting communicable (eg, HIV, Tb and malaria) and MNC conditions. Primary prevention of CVD, and treatment of other chronic conditions, depends on long-term patient-centred healthcare, trained personnel and well-functioning referral systems.[@R31] Health-information systems, sustainable delivery of drugs and regulatory capacities to manage private actors is also important in the implementation of primary prevention into the health system in Ethiopia. These are key challenges that policy makers need to handle when deciding whether primary prevention should be scaled-up in a country where the majority of the population live in rural areas. If only the interventions for CVD with the lowest ICERs, within the CVD category, were scaled-up by 20% in Ethiopia (primary prevention of CVD for individuals with \>35% risk of CVD; ASA, streptokinase and ACE-inhibitor for treatment of acute myocardial infarction; ASA, beta-blocker, statin and ACE-inhibitor as secondary prevention after myocardial infarction and ASA, statin and ACE-inhibitor as secondary prevention after stroke), total annual health benefit is expected to be 122 600 DALYs averted and budget impact is estimated to be around US\$21.3 million (US\$0.20 per capita).

Lessons: mental health {#s5-3}
----------------------

The mental health interventions have the highest ICERs of the ones we considered, and these interventions are seen, with low and wide bars, in the right corner of [figure 2](#F2){ref-type="fig"}. In the CEA by Strand *et al*,[@R13] we found that treatment of depression with antidepressants (SSRI) cost US\$636/DALY averted (1.6 DALYs averted per US\$1000 invested) and is expected to avert 19 900 DALYs in total. The combination 18 hours of psychotherapy and older antidepressants (TCA) for preventing relapse of depression, gives an ICER at US\$1134/DALY averted (0.9 DALYs averted per US\$1000 invested) and a net health benefit of 27 900 DALYs averted. Treatment of epilepsy with phenobarbital cost US\$448/DALY averted (2.2 DALYs averted per US\$1000 invested) and a net health benefit of 53 500 DALYs averted. Previously, we have applied a methodology of Extended Cost-Effectiveness Analysis to this CEA of mental and neurological healthcare in Ethiopia. Around 80% of the investments for scaling-up treatment and maintenance of depression was expected to be returned in the form of productivity gains.[@R26] Treatments of disorders such as schizophrenia and bipolar disorders have higher ICERs and lower expected health benefits, but prioritising such services could be justified by assigning higher priority to more severe diseases.[@R5] Whether it is acceptable to introduce interventions with high ICERs due to other fairness concerns like severity of disease are important for policymakers to discuss and decide on. If so, the cost-effectiveness threshold for less severe diseases must be lower. If only the most cost-effective interventions for each of the mental and neurological conditions were scaled-up by 30%--75% in Ethiopia (SSRI and psychotherapy for depression; lithium for bipolar disorder; risperidone for schizophrenia and phenobarbital for epilepsy), total annual cost is estimated to be around US\$156 million (US\$1.5 per capita) and the total health benefit expected to be 102 000 DALYs averted.

Contextualisation processes: thresholds and building health economic capacity {#s6}
=============================================================================

In Ethiopia, as in most other countries, there is a strong pressure to implement interventions which are not cost-effective. Such investments can level down rather than level up population health by displacing alternative health interventions. One example is dialysis treatment for end-stage kidney diseases. While the ICER of this intervention is far higher than the ICERs presented in our study, many African countries are now providing dialysis treatment in an increasing scale.[@R32]

Following suggestions by Claxton, Woods and others,[@R34] we believe previous cost-effectiveness thresholds were not well-founded on empirical grounds and may not indicate the actual opportunity costs of decisions.[@R36] New interventions can only be financed within existing budget constraints. Cost-effectiveness thresholds therefore become important in healthcare priority setting. Beneficial interventions are at risk of being displaced if less cost-effective interventions are introduced into the healthcare system without additional funding. As a consequence, less population health may be achieved if cost-effectiveness thresholds are too high. A cost-effectiveness threshold is not suggested here, but we use a threshold of US\$2000 per DALYs averted in the net health benefit analysis as an example. Budget threshold decisions are up to policy makers to decide on. Such threshold discussions are important in order to succeed with a gradual and realistic scale-up of high priority services in the years to come. By rank ordering all these 61 interventions according ICERs, and excluding dominated interventions, and by presenting the expected net health benefits and budget impact of these interventions, we hope to provide policymakers accessible evidence that can be used to assess willingness to pay for these essential healthcare services.

In these analyses, suboptimal target coverage levels are used. Target coverages were set based on discussion with experts from the different national health programmes in Ethiopia and all policy makers preferred analyses based on what they saw as feasible and realistic target coverage levels. This deviates from the WHO-CHOICE recommendation to estimate cost per health gain if interventions are implemented at full scale. Since ICERs in the models were not sensitive to target coverage levels (multiple levels were tested), we decided to adhere to demands of policy makers of applying what they saw as feasible targets.

Although our analysis is not exhaustive of all possible health interventions, we have demonstrated the importance of generating policy relevant and contextualised evidence. One way of facilitating systematised and explicit priority setting is to train policy makers in doing CEAs with contextualised data and visualisation of results. Long-term investments in training and close collaborations have been crucial in the development of the three studies presented here. Now, the Ethiopian coauthors of these CEAs provide technical support in national policy priority setting processes and independently conduct local CEAs. In addition, they are key in establishing a new Addis Ababa Centre for Ethics and Priority Setting (ACEPS) that aim to train decision makers in neighbouring African countries to conduct health economic evaluations and systematic priority setting.

Conclusion {#s7}
==========

A comprehensive ranking of interventions in league tables provides comparability across categories of interventions and gives a clear presentation of evidence and opportunity cost. In systematic priority setting, such evidence should be considered together with concerns for equity and financial risk protection. An annual US\$2.8 investment per capita in 22 interventions in Ethiopia can increase coverage by 20%--75% and around 0.5 million net DALYs averted is expected in return in total per year---with a willingness to pay threshold at US\$2000 per DALY averted. Capacity building is an important element in resource-constrained settings, as the demand for health economic evaluations are immensely high.
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